Anti-CD3 x Anti-FcRH5 Bispecific Antibody (IgG-IgG) (BSIG-H255)

Anti-CD3 x Anti-FcRH5 Bispecific Antibody (IgG-IgG) is designed to be generated by crosslinking two full length IgGs, anti-CD3 and anti-FcRH5 parental antibodies. A stable linkage is formed between the two antibodies. This BsAb can retarget T cells to tumor cells. It is designed for the research of Multiple myeloma (MM); B cell malignancies therapy.

Datasheet

Specifications

Targets

CD3 & FcRH5

Type

IgG-IgG

Species Reactivity

Human

Target 1

CD3

Host Animal 1

Human

Target 2

FcRH5

Host Animal 2

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Multiple myeloma (MM); B cell malignancies

Targets

Target 1

CD3

Gene ID

916

UniProt ID

P07766

Alternative Names

CD3; CD3E; CD3e molecule; Cluster of differentiation 3; CD3e molecule, epsilon (CD3-TCR complex); T3E; TCRE; IMD18; T-cell surface glycoprotein CD3 epsilon chain; CD3-epsilon; T-cell surface antigen T3/Leu-4 epsilon chain; CD3e antigen, epsilon polypeptide (TiT3 complex); T-cell antigen receptor complex, epsilon subunit of T3

Target 2

FcRH5

Gene ID

83416

UniProt ID

Q96RD9

Alternative Names

FCRL5; Fc receptor like 5; CD307; FCRH5; IRTA2; BXMAS1; CD307e; PRO820

Welcome! For price inquiries, we will get back to you as soon as possible.

To order, please email

INQUIRY

Online Inquiry

45-1 Ramsey Road, Shirley, NY 11967, USA
Email:
Fax: 1-631-207-8356
Or Call
Tel: 1-631-381-2994